Finding Optimal Targets for Complement-Based Cancer Therapy
Time: 10:00 am
day: Day Two
Details:
- Despite strong preclinical evidence on a role of complement in promoting cancer, complement-based cancer therapies have not yet advanced to the clinic
- Recent pre- and clinical studies suggest that progression of several subsets of renal cell carcinoma can be driven by complement-mediated mechanisms, therefore, these subsets are potential targets for complement-based intervention
- Levels of complement fragments in plasma associate with the response to immune checkpoint inhibitors
